FDA Approves Abuse-Deterrent, Extended-Release Oxycodone/Naltrexone (Troxyca ER) for Pain…

The FDA has given the nod to Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride, Pfizer) extended-release capsules for oral use (CII) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Troxyca ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal (more…)

Pharmacist pleads guilty in NYC oxycodone scheme – ModernMedicine

family:arial,sans-serif”> family:arial,sans-serif”>
Pharmacist pleads guilty in NYC oxycodone scheme
ModernMedicine
In one of the largest opioid diversion schemes to be uncovered in New York, a former pharmacy owner and her husband have pled guilty to several charges related to a multimillion-dollar oxycodone distribution scheme. Pharmacist Lilian Jakacki, 50, in

Visit site:
Pharmacist pleads guilty in NYC oxycodone scheme – ModernMedicine

ANI Pharma Launches Oxycodone Capsules; FDA Approves Oxcarbazepine Tablets – Nasdaq


(RTTNews.com) – ANI Pharmaceuticals, Inc. ( ANIP ) announced Monday the commercial launch of Oxycodone HCl Capsules, 5mg. Trailing twelve-month sales for the product are $7.5 million according to IMS Health.

The company noted that it is the third Schedule II narcotic product to the company’s commercial portfolio and sixth new product introduction in the second quarter of 2016.

Oxycodone hydrochloride is an (more…)